Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System

BACKGROUND: Evidence about remdesivir-associated acute kidney injury (AKI) among patients with novel coronavirus disease 2019 (COVID-19) was controversial. AIM: To investigate the signal of disproportionate reporting of remdesivir-related AKI in COVID-19 patients over time with data from US Food and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaotong, Zhou, Liyuan, Gaggl, Martina, Kinlaw, Alan C., Gou, Zhuoyue, Xu, Yang, Wei, Jingkai, Wang, Tiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Short Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038360/
https://www.ncbi.nlm.nih.gov/pubmed/36964312
http://dx.doi.org/10.1007/s11096-023-01554-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038360/
https://www.ncbi.nlm.nih.gov/pubmed/36964312
http://dx.doi.org/10.1007/s11096-023-01554-4

Ejemplares similares